Table 2.
Laboratory tests including blood routine examination and clinical biochemistry at the time of baseline evaluation
| Variables | PAs-HSOS | BCS |
|---|---|---|
| ALT < 3× ULN, n/N (%) | 64.36%(65/101) | 94.74%(54/57) |
| ALT 3–8 × ULN, n/N (%) | 21.78%(22/101) | 3.51%(2/57) |
| ALT > 8 × ULN, n/N (%) | 13.86%(14/101) | 1.75%(1/57) |
| AST < 3 × ULN, n/N (%) | 55.88%(57/102) | 91.23%(52/57) |
| AST 3–8 × ULN, n/N (%) | 35.29%(36/102) | 8.77%(5/57) |
| AST > 8 × ULN, n/N (%) | 8.82%(9/102) | 0 |
| T-BIL <34.2 μmol/L | 52.94% (54/102) | 61.40% (35/57) |
| T-BIL 34.2–85.5 μmol/L, n/N(%) | 81.37% (83/102) | 33.33% (19/57) |
| T-BIL 85.5–136.8 μmol/L, n/N(%) | 7.84%(8/102) | 1.75%(1/57) |
| T-BIL > 136.8 μmol/L, n/N(%) | 10.78%(11/102) | 3.52%(2/57) |
| Cr < 1× ULN, n/N(%) | 79.52%(66/83) | 96.55%(56/58) |
| Cr 1–2 × ULN, n/N(%) | 18.07%(15/83) | 3.45%(2/58) |
| Cr > 2× ULN,n/N(%) | 2.41%(2/83) | 0 |
PAs-HSOS pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome, BCS Budd-Chiari syndrome, ALT alanine aminotransferase, AST aspartate aminotransferase, T-BIL total bilirubin, Cr creatinine, ULN upper limit of normal, LLN lower limit of normal